Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2003;102:294-300
© 2003 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, R. M.
Right arrow Articles by Silver, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, R. M.
Right arrow Articles by Silver, R. M.

ORIGINAL RESEARCH

Anticardiolipin and Anti–ß2-Glycoprotein-I Antibodies in Preeclampsia

Richard M. Lee, MD, Melissa A. Brown, MD, D. Ware Branch, MD, Kenneth Ward, MD and Robert M. Silver, MD

From Phoenix Perinatal Associates, Obstetrix Medical Group, Phoenix, Arizona; and Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah.

Address reprint requests to: Robert M. Silver, MD, University of Utah Medical Center, 50 N. Medical Drive, Room 2B200, Salt Lake City, UT 84132; E-mail: bsilver{at}hsc.utah.edu.

OBJECTIVE: To estimate whether antiphospholipid antibodies, specifically anticardiolipin and anti–ß2-glycoprotein-Iantibodies, are associated with preeclampsia.

METHODS: Plasma was prospectively obtained from four groups of pregnant women: those with 1) mild preeclampsia (n = 109); 2) severe preeclampsia (n = 134); 3) hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (n = 57); and 4) normotensive controls (n = 100). Anticardiolipin and anti–ß2-glycoprotein-I levels were determined by enzyme-linked immunoassay.

RESULTS: Subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have significantly elevated levels of immunoglobulin G (IgG) and IgM anticardiolipin and anti–ß2-glycoprotein-I antibodies compared with normotensive controls (P > .05, Kruskal–Wallis). Similarly, subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have a significantly higher proportion of women testing positive for each autoantibody compared with normotensive controls ({chi}2). The proportion of patients testing positive for anticardiolipin and anti–ß2-glycoprotein-I antibodies were similar in patients with preeclampsia developing before and after 34 weeks’ gestation ({chi}2).

CONCLUSION: Circulating levels of both anticardiolipin and anti–ß2-glycoprotein-I antibodies were not increased in patients with mild preeclampsia, severe preeclampsia, or HELLP syndrome compared with normotensive controls. Our data do not support routine testing for anticardiolipin and anti–ß2-glycoprotein-I antibodies in women with preeclampsia.




This article has been cited by other articles:


Home page
 Mol Hum ReprodHome page
J. Francis, R. Rai, N. J. Sebire, S. El-Gaddal, M. S. Fernandes, P. Jindal, A. Lokugamage, L. Regan, and J. J. Brosens
Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome
Mol. Hum. Reprod., July 1, 2006; 12(7): 435 - 442.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
B. M. Sibai
Thrombophilia and Severe Preeclampsia: Time to Screen and Treat in Future Pregnancies?
Hypertension, December 1, 2005; 46(6): 1252 - 1253.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Obstetricians and Gynecologists.